Multi-functional nanocarriers to overcome tumor drug resistance

Cancer Treat Rev. 2008 Nov;34(7):592-602. doi: 10.1016/j.ctrv.2008.04.003. Epub 2008 Jun 5.


The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that lower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and light) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Disease Models, Animal
  • Drug Carriers / therapeutic use*
  • Drug Delivery Systems / methods*
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm*
  • Forecasting
  • Membrane Transport Modulators / pharmacology
  • Nanomedicine / trends
  • Nanoparticles / therapeutic use*
  • Neoplasms / drug therapy
  • Sensitivity and Specificity


  • Antineoplastic Agents
  • Drug Carriers
  • Membrane Transport Modulators